EUVIMEDEUVIMED entdecken
Crossref

PRO: Dose-dense Paclitaxel in Combination with Carboplatin is an Acceptable Standard in the Front-Line Management of Advanced Stage Ovarian Cancer

Robert L. Coleman

Clinical Ovarian Cancer · 2011

DOI: 10.1016/j.cloc.2011.04.011 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Ovarian Cancer, 2011. Verfasst von Robert L. Coleman. Die Arbeit nennt 20 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Coleman, R. L. (2011). PRO: Dose-dense Paclitaxel in Combination with Carboplatin is an Acceptable Standard in the Front-Line Management of Advanced Stage Ovarian Cancer. Clinical Ovarian Cancer. https://doi.org/10.1016/j.cloc.2011.04.011

Vancouver

Coleman RL. PRO: Dose-dense Paclitaxel in Combination with Carboplatin is an Acceptable Standard in the Front-Line Management of Advanced Stage Ovarian Cancer. Clinical Ovarian Cancer. 2011. doi:10.1016/j.cloc.2011.04.011

BibTeX
@article{Coleman2011,
  author = {Coleman, Robert L.},
  title = {PRO: Dose-dense Paclitaxel in Combination with Carboplatin is an Acceptable Standard in the Front-Line Management of Advanced Stage Ovarian Cancer},
  journal = {Clinical Ovarian Cancer},
  year = {2011},
  doi = {10.1016/j.cloc.2011.04.011}
}
Kostenlos starten →